BioSpace News Archive

Ryvu Therapeutics (WSE: RVU) announced today that the first patient has been dosed with the study drugs in a Phase II clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) – the RIVER-81 study (NCT06191263).

By combining years of clinical experience with cutting-edge research and development, IlluminOss Medical announces it has received FDA 510(k) clearance for a new Light-Emitting Diode (LED) Console to speed curing of its patented, light-cured implants.

Compass Pathways plc announced that management will hold a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference at 2:00 pm ET on February 13, 2024.

Xilio Therapeutics, Inc. will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the following investor conferences.

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Tyruko® in Germany from February 1.

Addex Therapeutics announced that the company has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $2.1 million through H.C. Wainwright as its sales agent.

Medivir AB announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, taking place in New York, New York on Thursday, February 8, 2024 at 2:00 p.m. ET.